Assessing Tumor Response and IMRT Treat Plan After IC Based on FDG-PET/CT for Locally Advanced HNSCC

Inclusion Criteria:

* Male or female patients aged 18 years or over;
* Histologically confirmed locally advanced (stage III and IV) head and neck squamous cell carcinoma (HNSCC);
* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1;
* Signed written informed consent approved by the Lithuanian Bioethics Committee (LBEC);

Exclusion Criteria:

* Positive serum pregnancy test in women of childbearing potential or breastfeeding;
* Presence of distant metastasis;
* Second primary tumor;
* History of other malignancy within the last 5 years;
* Recurrent head and neck cancer;
* Serious uncontrolled concomitant disease that would contraindicate the use of any drugs use in this study as chemotherapy or radiotherapy; ;
* Inadequate organ function, evidenced by the following laboratory results:

  1. Absolute neutrophil count \<1,500 cells/mm3;
  2. Platelet count \<100,000 cells/mm3;
  3. Hemoglobin \<9 g/dL;
  4. Total bilirubin greater than the upper limit of normal (ULN);
  5. AST (SGOT) or ALT (SGPT) \>1,5 x ULN;
  6. Alkaline phosphatase levels \>2,5 x the ULN;
  7. Serum creatinine \>2,0 mg/dl or 177 umol/l.